Renalytix plc

NEW YORK, June 30, 2026 /PRNewswire/ -- Renalytix PLC (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, today announced results published in the peer-reviewed medical journal Diabetes, Obesity and Metabolism from its most comprehensive real-world evidence (RWE) study to date for its FDA-approved kidneyintelX.dkd test. The post KidneyIntelX® Delivers Unprecedented Two-Year Real-World Outcomes in Diabetic Kidney Disease: No Comparable Risk Assessment Tool Exists appeared first on Renalytix.

NEW YORK and BOSTON, May 12, 2026 /PRNewswire/ -- Renalytix PLC (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, and Carna Health, an AI-enabled digital health company revolutionizing chronic disease prevention, both leaders in improving outcomes in chronic kidney disease (CKD), today announced a landmark partnership designed to transform how health systems identify, stratify, and manage chronic kidney disease and its interconnected cardiovascular-kidney-metabolic (CKM) complications. The post Renalytix™ and Carna Health Partner to Solve Kidney Disease Crisis: Bridging the Existing Gap Between Population Screening and Precision Intervention appeared first on Renalytix.

Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine company with kidneyintelX.dkd , the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, and MVP Health Care ("MVP") , a not-for-profit health insurer that provides services to 700,000 members in the northeastern part of the United States, have joined forces to mitigate the progression of chronic kidney disease in their insured type 2 diabetes patient population.Read More The post MVP Health Care and Renalytix Partner to Bring Life-Changing Kidney Disease Testing to Local Communities appeared first on Renalytix.

Renalytix plc American Depository Shares (ADSs) begin trading on OTCQB Venture Market under symbol “RNLXY” effective from Market Open on October 8, 2024 LONDON and NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitroRead More The post Commencement of trading on OTCQB in the United States appeared first on Renalytix.

LONDON and NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces aRead More The post Renalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond US appeared first on Renalytix.

Throughout the hearings process and pending the Panel’s decision, the Company’s ADSs will continue trading on The Nasdaq Global Market under the symbol “RNLX” LONDON and NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (Nasdaq: RNLX) (LSE: RENX) announces that it has formally submitted aRead More The post Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination appeared first on Renalytix.

Company has Achieved Prerequisites for Growing Test Adoption with FDA Authorization, Clinical Outcomes Data, Inclusion in Clinical Guidelines, and Broad Insurance Coverage LONDON and NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) -- Renalytix plc  (NASDAQ: RNLX) (LSE: RENX) announces that on June 13,Read More The post Medicare Issues Final Coverage Determination for kidneyintelX.dkd appeared first on Renalytix.

LONDON and SALT LAKE CITY - 28 May 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that O. James Sterling will step down from his role as Chief Financial Officer of the Company as of 24 May 2024 and will remain at the Company until 10 June 2024. The Board has appointed Joel R. Jung as Interim Chief Financial Officer, effective immediately while a handover period takes place. The post Management Change appeared first on Renalytix.